

Listing and evaluation of the results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.

Survey of 30 January 2019

Adviser:

Prof. Dr. med. Kai Gutensohn

MVZ aescuLabor Hamburg GmbH - amedes
Haferweg 36
22769 Hamburg

Tel.: +49 40 334411 880

Mail: kai.gutensohn@amedes-group.com

217

Haematology 11 - Stem/Progenitor Cells (CD 34)

Analyte	Sam- ple	Unit	Your value	Target value	TV- Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
CD34+ Events	11	/μl	67.0	65.7	SV	52.6	78.8	2.0%	0,225	+	
	12		173	193	SV	154	232	-10.4%	-1,27	+	
Leucocytes	11	/μl	10218	9858	SV	7886	11830				
	12		17241	17567	SV	14054	21080				
CD45+ events (single platform)	11	/μl	8853	9346	SV	7477	11215				
	12		15967	17234	SV	13787	20681				
Viable CD45+ Events	11	/μl	8415	8816	SV	7053	10579				
	12		15206	16038	SV	12830	19246				
Viable CD34+ Events	11	/μl	64.0	63.5	ET	50.8	78.0	0.8%	0,093	+	
	12		165	187	SV	150	224	-11.8%	-1,46	+	
Viable CD34+ Events per viable CD45+ Events	11	%	0.770	0.730	SV	0.584	0.876				
	12		1.09	1.17	SV	0.936	1.40				

Analyte	Sam- ple	Your unit	Stated value	Conversion factor	Method	Manu- facturer	Device	Sample reception date	Sample processing date
CD34+ Events	11		67.0	1.00	222	BN	BN04	01/24/19	01/25/19
	12		173	1.00					
Leucocytes	11		10218		222	BN	BN04	01/24/19	01/25/19
	12		17241						
CD45+ events (single platform)	11		8853		222	BN	BN04	01/24/19	01/25/19
	12		15967						
Viable CD45+ Events	11		8415		222	BN	BN04	01/24/19	01/25/19
	12		15206						
Viable CD34+ Events	11		64.0	1.00	222	BN	BN04	01/24/19	01/25/19
	12		165	1.00					
Viable CD34+ Events per viable CD45+ Events	11		0.770		222	BN	BN04	01/24/19	01/25/19
	12		1.09						

Individual summary of results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.

Survey of 30 January 2019



217

Haematology 11 - Stem/Progenitor Cells (CD 34)

CD34+ Events (μl , N = 79)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11	65.7	52.6 - 78.8	65.7	8.80	79	96.2	94.9	
	12	193	154 - 232	193	8.19	79	98.7		


Rate of success: 94,9%



Leucocytes (μl , N = 16)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11	9858	7886 - 11830	9858	11.1	16			
	12	17567	14054 - 21080	17567	7.25	16			


Rate of success: 87,5%



CD45+ events (single platform) (μl , N = 70)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11	9346	7477 - 11215	9346	10.9	70			
	12	17234	13787 - 20681	17234	7.82	70			


Rate of success: 90%



Viable CD45+ Events (/μl, N = 91)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11	8816	7053 - 10579	8816	15.2	91			
	12	16038	12830 - 19246	16038	12.0	91			



Rate of success: 81,3%



Viable CD34+ Events (/μl, N = 91)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11	63.5	50.8 - 78.0	63.5	8.44	91	96.7	94.5	
	12	187	150 - 224	187	8.07	91	95.6		

Rate of success: 94,5%



Viable CD34+ Events per viable CD45+ Events (% , N = 91)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11	0.730	0.584 - 0.876	0.730	14.2	91			
	12	1.17	0.936 - 1.40	1.17	10.4	91			

Rate of success: 83,5%

